Search the Newsreel

Banco Macro SA (BMA) Institutional Confidence

Banco Macro SA (BMA) has an institutional shareholding score of 3.00, ranking 250 out of 395 in the Banking Services industry, with institutional shareholding decreasing by 21.66% quarter-over-quarter to 10.94%. ETHSX is the largest institutional shareholder, holding 0.62% of outstanding shares. The article also …

BH Macro Tightens Capital Structure with Share Buyback

Macro Metals Posts A$2.004M in Quarterly Services Revenue as Nyapiri Macro Launches A$12.52M BHP Work Package

Macro Metals Reports A$2.004M Quarterly Services Revenue as BHP Work Package Delivery Begins

Wall Street Analysts See a 30.32% Upside in Banco Macro (BMA): Can the Stock Really Move This High?

Banco Macro (BMA) closed the last trading session at $90.8, gaining 1.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target …

BMA|Banco Macro SA|Price:92.680|Chg%:+0.780

Banco Macro SA (BMA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Banco Macro SA (BMA), highlighting its current valuation score and P/E ratio. The company's valuation score is 8.34, placing it 169th in the Banking Services industry, and its P/E ratio is 24.93. The article notes that relevant …

BlackRock (MGNX holder) discloses 7.1% MacroGenics stake in Schedule 13G filing

BlackRock, Inc. has disclosed a 7.1% beneficial ownership stake in MacroGenics Inc. (MGNX), holding 4,503,913 shares of common stock as of June 30, 2026. This information was reported in a Schedule 13G filing, indicating that BlackRock has sole voting power over 4,447,312 shares and …

BMA or NABZY: Which Is the Better Value Stock Right Now?

Investors with an interest in Banks - Foreign stocks have likely encountered both Banco Macro (BMA) and National Australia Bank Ltd. (NABZY). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. Everyone …

MGNX|MacroGenics Inc|Price:3.732|Chg%:+0.062

This article provides a comprehensive stock analysis of MacroGenics Inc (MGNX) from TradingKey, highlighting its strong fundamentals, high growth potential, and "fairly valued" status. Despite recent market weakness, the company's revenue and net income have seen significant growth, and analysts have issued "Buy" ratings …

BH Macro Limited - Investor Statement

Banco Macro Number of Employees 2026 | Employee Count & Headcount Data

Banco Macro SA (BMA) reported approximately 9,865 total employees worldwide as of March 2026, marking a 7.6% growth since 2023 but a 0.8% decline year-over-year in 2026. The company, headquartered in Buenos Aires, Argentina, has its workforce concentrated primarily in Argentina (90.4%), with Spain …

Macrogenics Market Sentiment

This article analyzes market sentiment for MacroGenics (MGNX) through analyst consensus, short interest, options flow, and recent insider activity. It highlights a "Buy" consensus from 14 analysts with an average price target of $8, significant short interest of 9.3%, and bullish options flow. The …

Should Value Investors Buy Macro Bank (BMA) Stock?

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends …

BMA|Banco Macro SA|Price:92.160|Chg%:-0.030

Banco Macro SA (BMA) shows strong fundamentals and high growth potential, with its valuation considered fairly valued within the Banking Services industry. Institutional ownership is notably high, and analysts generally rate it as a "Buy" with a significant upside to its target price. Despite …

Banco Macro S.A. Stock 12‑Month Price Target Cut to $124.37, Implies 40% Upside

Banco Macro S.A.'s average price target has been adjusted to $124.37 from $125.35 by 8 analysts, with individual forecasts ranging from $85 to $173.85 per share. This updated target indicates a potential upside of approximately 40% from the July 24 closing price. The consensus …

MacroGenics, Inc. Revenue Breakdown – NASDAQ:MGNX

MacroGenics, Inc. (NASDAQ: MGNX) generated $149.50 million USD in revenue last year. The majority of this revenue, $87.18 million USD, came from its Collaborative and Other Agreements segment. The United States was the largest geographical contributor, accounting for the entire $149.50 million USD of …

Citizens reiterates MacroGenics stock rating ahead of ESMO data

Citizens has reiterated a Market Perform rating on MacroGenics Inc. (NASDAQ:MGNX) ahead of the ESMO 2026 conference, where MacroGenics will present data for its MGC026 antibody-drug conjugate and lorigerlimab LINNET study. The firm notes that MacroGenics shares are currently trading at a significant discount …

BH Macro Tightens Capital Base With Targeted Share Buyback

Banco Macro SA (BMA) Income Statement

This article provides a detailed quarterly and annual income statement for Banco Macro SA (BMA), offering insights into its financial performance, including total revenue, operating expenses, operating profit, and net income. It also includes an FAQ section to help users understand how to interpret …

Banco Macro SA Sponsored ADR Class B Revenue Breakdown – BCBA:ABMT

Banco Macro SA's revenue breakdown indicates that its primary segment, Banking and Related Activities, generated most of its revenue last year, totaling ‪4.74 T ARS. The largest contribution by country came from Argentina, matching the top segment's revenue. Overall, the company generated ‪4.55 T …

MacroGenics Inc (MGNX) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for MacroGenics Inc (MGNX), allowing users to evaluate the company's financial health and stability. It includes data on operating, investing, and financing cash flows, along with a definition and explanation of each cash …

Banco Macro S.A. ADR (representing Ten Class B) (BMA) Stock Price | Live Quotes & Charts | NYSE

This page provides live quotes and charts for Banco Macro S.A. ADR (BMA) stock on the NYSE, showing its current price, daily change, and options for viewing historical data. It also includes sections for analyst ratings, though none are currently available, and mentions earnings …

TradingKey

This page provides an income statement for MacroGenics Inc (MGNX), detailing its quarterly and annual financial performance. It includes metrics like total revenue, operating expenses, net income, and earnings per share, along with year-over-year comparisons. The data allows investors to analyze the company's operational …

MacroGenics Inc (MGNX) Institutional Confidence

MacroGenics Inc (MGNX) currently holds an institutional shareholding score of 5.00, placing it 132nd out of 386 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 68.70%, marking a 14.58% increase quarter-over-quarter. James Simons is the largest institutional shareholder.

MacroGenics slips on trial data for lead asset (MGNX:NASDAQ)

MacroGenics (MGNX) shares fell by nearly 6% following the release of updated results from an ongoing Phase 1 trial for its lead asset, MGC026. The drug, an antibody-based therapy, is being developed to target solid tumors. The trial data involved 74 patients.

MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

MacroGenics, Inc. announced a clinical update on its ongoing Phase 1 study for MGC026, a B7-H3-directed antibody-drug conjugate (ADC), for advanced solid tumors. Interim results, showing the achievement of a pre-specified response threshold in squamous cell carcinoma of the head and neck, will be …

BMA|Banco Macro SA|Price:89.110|Chg%:-2.350

Banco Macro SA (BMA) is trading at 89.110 USD, down 2.56%. The company has strong fundamentals and high growth potential, with a "Buy" rating from analysts and a target price of 117.00. Key figures show a market cap of 6.01B, a P/E TTM of …

Banco Macro SA (BMA) Stock Down 6.2% but Still Overvalued -- GF Score: 67/100

Banco Macro SA (BMA) shares dropped 6.2% to $91.63, yet GuruFocus assesses the stock as "Significantly Overvalued" with a GF Value™ of $31.73, indicating a substantial discrepancy from its intrinsic value. While the stock shows strong momentum (10/10), its valuation (1/10) and financial strength …

MGNX stock holds focus as MacroGenics plans and pipeline metrics matter

MacroGenics (MGNX) is a small-cap biotech company whose stock performance is heavily influenced by pipeline execution, balance sheet health, and financial metrics like revenue and cash use. Investors should focus on the company's reported numbers, program milestones, and clinical data readouts rather than broad …

BMA6137828 Bond Coupon Profile — Rate & Payments

This article provides a coupon profile for the BMA6137828 bond issued by Banco Macro S.A., detailing its interest rate and payment schedule. The bond has a current coupon rate of 8.00%, with the next interest payment scheduled for December 23, 2026. The article indicates …

MacroGenics’ MGC026 meets trial threshold in head and neck cancer

MacroGenics Inc. announced that its Phase 1 study for MGC026, an antibody-drug conjugate, met the pre-specified response threshold in the head and neck cancer cohort, allowing it to advance to Stage 2 enrollment. Interim results from the study, which has enrolled 74 patients, will …

BMA6137828 Bond Risk Profile

This article provides a risk profile for the Banco Macro S.A. bond BMA6137828, maturing on June 23, 2029, with an 8.0% coupon. It highlights various metrics for credit risk assessment, including security level, inflation protection, and issuer rating. Additionally, it mentions access to exclusive …

BMA stock trades steady as Banco Macro reports resilient earnings and capital ratios

Banco Macro (NYSE: BMA) has demonstrated resilient earnings and strong capital ratios, attracting investors despite Argentina's volatile macroeconomic conditions. The bank maintains double-digit returns on equity, robust capital adequacy, and a focus on cost efficiency, outperforming many regional peers. However, the valuation of BMA …

Acrophyte Hospitality Trust Closes Sale of US Hotel; Shares Up 7%

Acrow (ASX:ACF) Closes in Positive Territory—Can The Stock Rebuild Long-Term Momentum?